IL22 and inflammatory bowel disease: This suggests that IL-22 can act as an anti-inflammatory molecule against LPS and may be a novel therapeutic agent in IBD patients (Witte et al., 2010; Sonnenberg et al., 2011a; Sabat et al., 2014).